RS
IOVA icon

R Squared’s Iovance Biotherapeutics IOVA Stock Holding History

R Squared’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Sell
26,277
-606
-2% -$2.3K 0.06% 395
2026
Q1 		$94.4K Sell
26,883
-7,650
-22% -$24.5K 0.05% 374
2025
Q4 		$94.3K Buy
34,533
+18,490
+115% +$42.8K 0.04% 416
2025
Q3 		$34.8K Buy
16,043
+4,700
+41% +$11.1K 0.02% 513
2025
Q2 		$19.5K Buy
+11,343
New +$28.2K 0.01% 442

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

R Squared's IOVA Position: Q2 2026 in Review

R Squared reduced its Iovance Biotherapeutics (IOVA) stake by 2.3% in Q2 2026, selling an estimated $2.3K and leaving 26,277 shares worth $109K. The position accounts for 0.06% of the portfolio, ranked #395.

R Squared first reported a position in IOVA in Q2 2025 and has held it in 5 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • R Squared held 26,277 shares of Iovance Biotherapeutics worth $109K as of Q2 2026.
  • R Squared sold 606 Iovance Biotherapeutics shares in Q2 2026, an estimated $2.3K.
  • Iovance Biotherapeutics made up 0.06% of R Squared's portfolio in Q2 2026, its #395 holding.
  • R Squared first reported a position in Iovance Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.